DS Biopharma, a privately held Dublin-based company with a proprietary bioactive lipid technology platform, has launched Afimmune, a spin-off focused on approaches to treating fibrosis and fibrotic conditions. These includenon-alcoholic steatohepatitis (NASH) and atopic dermatitis, as well as other inflammatory and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), and…
DS Biopharma Spin-off to Focus on Fibrotic Diseases Like IPF, COPD
Metformin, a first line medication for the treatment of type 2 diabetes, reduces inflammation and pulmonary fibrosis in mice, suggests a study published in the Journal of Korean Medical Science.
Researchers at the Chinese Nanjing University School of Medicine in China discovered yet another microRNA that contributes to the development of lung fibrosis. MicroRNA are small molecules known to control gene activity. The study, “MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1,” published in the…
Childhood cancer survivors are at an increased risk of developing lung fibrosis for up to 25 years after their initial cancer diagnosis, analyses of data from the Childhood Cancer Survivor Study show. The report, “Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood…
Certain distinctive genetic differences or variations, including in genes involved in mucus production, were found to be significantly predominant in European populations of patients with idiopathic pulmonary fibrosis (IPF), according to the study, “Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations” published in…
Researchers at Johns Hopkins University have identified a new gene that, when mutated, increases the risk for pulmonary fibrosis and emphysema by reducing the activity of telomerase, the enzyme that maintains the protective caps, or telomeres, on chromosomes. The study, “Loss-of-function mutations in the RNA biogenesis factor…
Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue which is known as fibrosis. Because of the disease, the lungs lose their ability to properly function making it hard to transport oxygen into the…
Humanetics of Minneapolis was awarded a federal grant to continue developing its proprietary BIO 300 radiation modulator to treat delayed effects of acute radiation exposure in the lungs. The $597,000 grant from the the National Institute of Allergy and Infectious Diseases (NIAID) will cover two years of research in a collaborative effort…
A collaborative research effort identified new pathways involved in fibrosis using a software tool known as “Regeneration Intelligence,” which evaluated perturbations in several signaling pathways in lung and liver fibrosis, and in glaucoma. The research, leading to two studies, was conducted by Insilico Medicine working with scientists at Atlas Regeneration, Vision Genomics, and Howard University. The…
FibroStatin recently announced the development of a therapeutic agent against lung fibrosis called T12, building on the entirely new concept of blocking the transition of blood vessel endothelial cells to the more aggressive mesenchymal cells that contribute to fibrosis. This so-called endothelial-mesenchymal transition (EMT) is crucial during processes such as wound…
